article thumbnail

FDA Warns of Toxic Lead in Cinnamon Products

Drugs.com

The FDA urged folks to throw away and not buy the following brands of. WEDNESDAY, March 6, 2024 -- The U.S. Food and Drug Administration issued a health advisory Wednesday warning consumers that six brands of ground cinnamon are tainted with lead.

FDA 145
article thumbnail

Zepbound, Mounjaro shortages are resolved, FDA confirms

BioPharma Drive: Drug Pricing

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Duchenne approval exposes FDA rift over Sarepta gene therapy

BioPharma Drive: Drug Pricing

Peter Marks’ decision to override the objections of agency staff and broaden use of Elevidys could have a “lasting impact” on gene therapy as well as the FDA, one analyst wrote.

Therapies 135
article thumbnail

Proposed FDA Rule Targets Asbestos in Talc Cosmetic Products

Drugs.com

Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing cosmetics for asbestos, a known carcinogen linked to serious illnesses such as lung and ovarian. FRIDAY, Dec. 27, 2024 -- The U.S.

FDA 111
article thumbnail

FDA Can’t Reclassify Its Way Out of Reviewing 100,000 LDT Submissions

FDA Law Blog: Biosimilars

Mullen — On January 31, 2024, FDA announced its intent to initiate the reclassification process for most in vitro diagnostic (IVD) products that are currently class III (high risk) into class II (moderate risk). This is to say nothing of the expected doubling of annual device submissions FDA expects it will then receive on an ongoing basis.

FDA 116
article thumbnail

FDA makes end of Zepbound, Mounjaro shortage official

BioPharma Drive: Drug Pricing

Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded versions.

FDA 120
article thumbnail

5 FDA decisions to watch in the second quarter

BioPharma Drive: Drug Pricing

The FDA could soon expand use of two multiple myeloma cell therapies as well as a top-selling medicine from Sanofi and Regeneron, while Pfizer’s years of gene therapy work might finally pay dividends.

FDA 122